109Pd labeled 5,10,15,20-tetrakis[4-carboxymethyleneoxyphenyl]porphyrin: a Potential Agent for Targeted Tumor Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1874-4729|5|4|340-347

ISSN： 1874-4710

Source： Current Radiopharmaceuticals, Vol.5, Iss.4, 2012-10, pp. : 340-347

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles

By Skidan Igor   Dholakia Parita   Torchilin Vladimir  

Journal of Drug Targeting, Vol. 16, Iss. 6, 2008-07 ,pp. : 486-493

Informa Healthcare

Access to resources Recommend Favorite

VEGF in Tumor Progression and Targeted Therapy

By  

Current Cancer Drug Targets, Vol. 13, Iss. 4, 2013-05 ,pp. : 423-443

Bentham Science Publishers

Access to resources Recommend Favorite

Remacemide: potential as adjunctive therapy in PD

By  

Inpharma, Vol. 1, Iss. 1283, 2001-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Targeted Alpha-Particle Therapy with 227Th-Labeled Antibodies

By  

Current Radiopharmaceuticals, Vol. 1, Iss. 3, 2008-09 ,pp. : 209-214

Bentham Science Publishers

Access to resources Recommend Favorite

Endoglin for tumor imaging and targeted cancer therapy

By Paauwe Madelon   ten Dijke Peter   Hawinkels Lukas JAC  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 4, 2013-04 ,pp. : 421-435

Informa Healthcare

Access to resources Recommend Favorite